{"id":"W3034783173","doi":"10.1016/j.trecan.2020.05.009","title":"Clinical Development of BRAF plus MEK Inhibitor Combinations","year":2020,"lang":"en","type":"review","venue":"Trends in cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":352,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Company; Bristol-Myers Squibb Canada; Genentech; European Society for Medical Oncology; Exelixis; Prometheus; Roche; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; American Society of Clinical Oncology; AstraZeneca; Novartis; Spectrum Pharmaceuticals; Amgen; GlaxoSmithKline","keywords":"MEK inhibitor; Cancer research; Chemistry; Pharmacology; Medicine; MAPK/ERK pathway; Phosphorylation; Biochemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008348332,0.001057181,0.001723418,0.001000337,0.0001845437,0.001119179,0.001221464,0.001089105,0.005557346],"category_scores_gemma":[0.001004343,0.0002806069,0.0007831003,0.0007744572,0.0003897588,0.0009122512,0.0005068369,0.003434797,0.001816442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005553436,"about_ca_system_score_gemma":0.00069455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006651468,"about_ca_topic_score_gemma":0.002640109,"domain_scores_codex":[0.9998004,0.00004595229,0.00002252757,0.00004347075,0.00005934918,0.00002833805],"domain_scores_gemma":[0.999724,0.0001279432,0.00004539873,0.000008222833,0.00005333548,0.0000410758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004566463,0.0001988723,0.0001543537,0.00454149,0.0001229845,0.0001740905,0.00002429486,0.0005220821,0.001649535,0.001645758,0.02780221,0.9627076],"study_design_scores_gemma":[0.001315017,0.001337375,0.001898661,0.004007119,0.0004853161,0.001713379,0.0000515519,0.0005276144,0.00148041,0.00288174,0.9842595,0.00004230373],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006459283,0.9947895,0.000502563,0.0007363305,0.0004541693,0.00003248252,0.00006046466,0.00002650767,0.00275207],"genre_scores_gemma":[0.006890493,0.9859489,0.001065717,0.00206425,0.0005611489,0.00007525422,0.0002420707,0.00001180743,0.003140415],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005557346,"threshold_uncertainty_score":0.01859123,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1354341508561493,"score_gpt":0.4400165371099267,"score_spread":0.3045823862537773,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}